GCC Secretary-General Meets with Minister of State for Foreign Affairs of Bangladesh at Davos Forum    Saudi physics team wins 3 global awards in 2022 European Olympiad    SDRPY launches project to rehabilitate Haijat Al-Abed road    KSrelief Conducts 300 Surgeries as Part of Voluntary Medical Project to Combat Blindness in Al-Mukalla    SAMA governor, CMA chairman thank Saudi leadership for approving FinTech strategy    NDMC Closes the May 2022 Issuance under Saudi Arabian Government SAR-denominated Sukuk Program    Crown Prince discusses relations with members of US Congress    SFDA warns against Jif peanut butter products    KSrelief Participates in High-Level Regional Meeting on Youth    Women's green futsal team wins bronze in Gulf Games    Saudi Stock Exchange Main Index Ends Trading Higher at 12,300.86 Points    Cabinet to continue implementing initiatives and reforms to achieve Vision 2030 objectives    DCO, WEF launch initiative to boost global digital FDI flows    Uganda Supports Saudi Arabia's Bid to Host World Expo 2030    Aramco can't expand output capacity any faster, says CEO Amin Nasser warns of oil crunch    Consensus needed over digital technology for 'people and the planet'    International community urged to support new administration in Somalia    Global jobs market recovery 'has gone into reverse', warns UN labor agency    Saudi Press: Saudi Arabia Exerts Exceptional Efforts to Achieve Security and Stability in Yemen    Appeals court affirms termination of Wafa Insurance's financial restructuring    Saudi Vice Minister of Defense Visits CENTCOM Headquarters    In a Report to SPA .. SDAIA: Autonomous Vehicles Will Be Commercially Available in World by 2030, Will Account for 50% of Sales after 2045    Manchester City clinches Premier League title on dramatic final day    How Syrian singer Rasha Rizk dazzled millennials at Jeddah Season?    King Salman Park begins construction on its Royal Arts Complex    Shoura members propose equal blood money for men and women, Muslim and non-Muslim    KSrelief's Masam Project Dismantles 1,339 Mines within a Week in Yemen    British Investors Express Interest in Investing in Saudi Arabia's Food, Drug Market    7 Die in Philippine Ferry Fire; over 120 Rescued from Water    Ithra Participates in Cannes Film Festival with New Films to Support Saudi Talents    Exclusive launching of Michael Schumacher Digital Experience at Jeddah F1 Grand Prix    MoH allows 6 categories to receive second booster dose    Mbappé signs new 3-year PSG deal after rejecting Real Madrid    Saudi Aramco: London Championship to Witness Participation of World's Best Female Golfers    Saudi woman finds out she is male after 20 years    Saudi Arabia Heads to Cannes International Film Festival to Promote Country's Flourishing Industry and Support Emerging Talent on World Stage    President of SAFF Participates in AFC General Assembly Meeting    Saudi Athletes Achieve Great Victories in the 2nd Day of the GCC Games Tournament in Kuwait    Jazan Hosts West Asian Beach Soccer Championship    Bollywood actor's tweet reignited debate over Hindi as India's national language    SFDA Advises to Wash Dates Well Before Eating    SFDA Advises Against Mixing Surplus of Iftar and Suhoor with Different Foods or Surplus from Other Days    Ministry calls on imams to avoid long supplications in Tahajjud Prayer    Nothing wrong with a Muslim celebrating birthdays, says Saudi scholar    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



China approves Sinopharm coronavirus vaccine, vows free shots for all citizens
Published in The Saudi Gazette on 31 - 12 - 2020

China approved its first homegrown coronavirus vaccine for general public use on Thursday, with officials promising to provide the general public with free inoculations.
The approval comes a day after its manufacturer, state-owned pharmaceutical giant Sinopharm, said the vaccine is 79.34% effective, citing an interim analysis of Phase 3 clinical trials.
Though no detailed efficacy data for the vaccine has been released, the decision to grant approval underscores claims made by Chinese officials in recent weeks over the safety and effectiveness of the country's domestically produced vaccine candidates.
China is aiming to inoculate 50 million people with domestic COVID-19 vaccines ahead of February's Lunar New Year celebrations. It has also drastically scaled up its vaccine emergency use program in recent weeks.
Zeng Yixin, the vice minister of China's National Health Commission, said at a news conference Thursday that the Sinopharm vaccine will be provided free of charge to Chinese citizens.
"Vaccine is a public good by its nature, and the price may vary based on the scale of use, but an important premise is that it will be provided to the public for free," Zeng said.
Since Dec. 15, more than 3 million vaccine doses have been administered to "key groups," Zeng said. That's on top of the 1.5 million doses administered to "high-risk groups" by the end of November, he added.
Among those inoculated, fewer than 0.1 percent developed a light fever, and about two people per million developed "relative serious adverse reactions" such as allergies, according to Zeng.
The next step is to inoculate vulnerable groups such as the elderly and people with underlying diseases, before vaccinating the general population, Zeng said, without offering more details on how the vaccines will be provided for free.
A Sinopharm company executive said Thursday the vaccine's Phase 3 trials covered more than 60,000 people, while detailed data will be released later and published in scientific journals at home and abroad.
An official with China's drug regulator said the vaccine's clinical trials are still ongoing, and its manufacturer will be required to submit follow-up data to authorities.
The Sinopharm vaccine is less effective than those developed by Pfizer-BioNTech and Moderna, which have an efficacy rate of about 95 percent. Russia says its Sputnik V vaccine is 91 percent effective.
And the vaccine's efficacy rate of 79 percent is lower than the 86 percent announced by the United Arab Emirates for the same vaccine on Dec. 9. The UAE based its results on an interim analysis of late-stage clinical trials conducted there from July. It has since approved the vaccine for public use.
The Sinopharm vaccine has a higher efficacy rate than the one developed by the UK's Oxford University and AstraZeneca, which averaged 70 percent. On Wednesday, the UK became the first country to approve that vaccine for public distribution.
Sinopharm's results were announced weeks after its global competitors. And with a lack of details, it remains unclear whether the information provided will be enough to dispel skepticism over the quality of Chinese vaccines.
Nevertheless, the announcement could still pave the way for the vaccine's large-scale rollout both within China and globally.
China is ready to send hundreds of millions of doses to countries that have conducted last-stage trials for its leading vaccine candidates. Chinese leaders have also promised a growing list of developing countries' priority access.
Beijing is using the global campaign as a soft power tool, analysts say, to try to repair any damage to its image from its early mishandling of the coronavirus pandemic.
Aside from the approved Sinopharm vaccine, China has four coronavirus candidates that have reached Phase 3 clinical trials — the last and most important step of testing before regulatory approval is sought. Having largely eliminated the spread of coronavirus inside its borders, Chinese drugmakers had to look abroad for places to test the efficacy of their vaccines. Together, they have rolled out Phase 3 trials in at least 16 countries.
Sinopharm's two vaccine candidates, including the one approved in China, have rolled out Phase 3 trials in 10 countries, mostly in the Middle East and South America.
Sinopharm chairman Liu Jingzhen said last month that dozens of countries have requested to buy the company's vaccines. He did not name the countries or elaborate on the number of doses they proposed, but he said CNBG was capable of producing more than a billion doses in 2021.
Compared with Pfizer and Moderna, Sinopharm's vaccines do not require freezing temperatures for storage, making transport and distribution much easier — especially in developing countries that lack cold storage capacities. — Courtesy CNN


Clic here to read the story from its source.